Expression of MALAT1 in the peripheral whole blood of patients with lung cancer

Guo, Fengjie; Yu, Fenglei; Wang, Jing; Li, Yongwen; Liu, Ying; Li, Zhigang; Zhou, Qinghua

doi:10.3892/br.2015.422

Cited by 53 publications

(51 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six studies with eight datasets were finally included in the meta‐analyses after a systematic search of the databases was performed. The identification process of the studies is shown in Figure .…”

Section: Resultsmentioning

confidence: 99%

“…Because of minimal invasion and easy sample collection, serological biomarkers for lung cancer diagnosis or screening are of great interest . Several studies have recently evaluated long noncoding RNA MALAT1 expression in serum or plasma of NSCLC patients and discussed its diagnostic performance . However, due to limited statistical power caused by a small sample size, the findings of the publications were inconclusive.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non‐small cell lung cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background: To investigate the diagnostic efficacy of long noncoding RNA metastasis-associated in lung adenocarcinoma transcript l (MALAT1) as a candidate serological biomarker for non-small cell lung cancer (NSCLC). Methods: Diagnostic studies relevant to circulation long noncoding RNA MALAT1 as a candidate serological biomarker for NSCLC were electronically systematically searched in PubMed, EMBASE, EBSCO and CNKI databases. Suitable studies were included in the meta-analysis by pooling the diagnostic sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odds ratio (DOR) and area under the symmetric ROC curve (AUC) through a random or fixed effects model. Deeks' funnel plot was applied for publication bias evaluation. Results: Six studies with eight datasets were finally included in the meta-analysis after a systematic search of the databases was performed. The pooled diagnostic sensitivity, specificity, +LR, −LR and DOR were 0.81 (95% CI:0.78-0.84), 0.67 (95% CI:0.63-0.71), 2.61 (95% CI:1.81-3.71), 0.28 (95% CI:0.19-0.43) and 13.73 (95% CI:6.19-30.44), respectively. The pooled area under the ROC curve (AUC) were 0.8663 and 0.8658, respectively by symmetric and asymmetric methods. Conclusion: Based on the results of our study, serum long noncoding RNA MALAT1 is a promising biomarker for NSCLC screening. However, due to its low specificity, MALAT1 positive cases need further validation for NSCLC by other diagnostic methods such as radiology, cytology, etc.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non‐small cell lung cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Three studies reported expression of lncRNAs in whole blood samples, measured by RT-PCR or qRT-PCR. Two of the studies found that the expression of MALAT1 in whole blood samples was lower in patients diagnosed with NSCLC than in the rest of the population, in contrast to the upregulated expression of MALAT1 in the tissues of NSCLC patients [124,125]. Another study found elevated SCAL1 expression in the airways of smokers and several lung cancer cell lines [126].…”

Section: Circulating Noncoding Rnasmentioning

confidence: 99%

Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review

et al. 2019

View full text Add to dashboard Cite

Lung cancer represents a genetically heterogeneous disease with low survival rates. Recent data have evidenced key roles of noncoding RNAs in lung cancer initiation and progression. These functional RNA molecules that can act as both oncogenes and tumor suppressors may become future biomarkers and more efficient therapeutic targets. In the precision medicine era, circulating nucleic acids have the potential to reshape the management and prognosis of cancer patients. Detecting genomic alterations and level variations of circulating nucleic acids in liquid biopsy samples represents a noninvasive method for portraying tumor burden. Research is currently trying to validate the potential role of liquid biopsy in lung cancer screening, prognosis, monitoring of disease progression, and treatment response. However, this method requires complex detection assays, and implementation of plasma genotyping in clinical practice continues to be hindered by discrepancies that arise when compared to tissue genotyping. Understanding the genomic landscape of lung cancer is essential in order to provide useful and innovative research in the age of patient-tailored therapy. In this landscape, the noncoding RNAs play a crucial role due to their target genes that dramatically influence the tumor microenvironment and the response to therapy. This article addresses present and future possible roles of liquid biopsy in lung cancer. It also discusses how the complex role of noncoding RNAs in lung tumorigenesis could influence the management of this pathology.

show abstract

“…MALAT1 представляет собой перспективный диагностический биомаркер, обнаруживаемый в крови, для эффективного выявления рака легких. Одно исследование показало повышенные уровни экспрессии MALAT1 в цельной крови пациентов с метастатическим раком легкого [38].…”

Section: циркулирующие Incrnas как биомаркеры ракаunclassified

Long Non-Coding RNA as the Newest Perspective Biomarkers in Cancer

Beylerli

Beilerli

Gareev

2019

Innovative Medicine of Kuban

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a large group of non-coding RNAs (ncRNAs) which are more than 200 nucleotides in length. LncRNAs, as regulation factors, show an important role in complex cellular processes, such as apoptosis, growth, differentiation, proliferation, etc. Recently, the results of many studies have also shown their significant role in carcinogenesis. Endogenous lncRNAs are known to be secreted by tumor cells in human biological fluids in the form of microvesicles, exosomes, or protein complexes, thereby forming circulating lncRNAs that do not degrade under the influence of RNases and are in a stable state. Compared with traditional biomarkers, as proteins circulating lncRNA have several advantages that will allow to consider circulating lncRNA as a new potential biomarker for various diseases. Aberrant expression of lncRNAs was observed in cancer patients. In this context, endogenous lncRNAs can regulate the main characteristics of cancer cells, controlling the expression of oncogenes associated with their suppressive and oncogenic functions. Consequently, circulating lncRNAs can be excellent biomarkers for cancer. Knowledge of the molecular mechanisms by which lncRNAs contribute to the development of cancer will improve our understanding of etiology, and open up horizons for the development of new biomarkers. In this paper, we will analyze current knowledge about the change in the expression profile of circulating lncRNAs in cancer, as well as methods for their detection.

show abstract

Expression of MALAT1 in the peripheral whole blood of patients with lung cancer

Cited by 53 publications

References 19 publications

Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non‐small cell lung cancer: A meta‐analysis

Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non‐small cell lung cancer: A meta‐analysis

Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review

Long Non-Coding RNA as the Newest Perspective Biomarkers in Cancer

Contact Info

Product

Resources

About